Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has finalized an acquisition of a mesalazine suppository product from Jiangsu Anbison Pharmaceutical. This product is indicated for the treatment of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn’s disease. The financial details and other specific terms of the deal were not disclosed.
Ethypharm has been a significant player in the Chinese market for oral mesalazine, under the brand Etiasa, since 1997, and currently holds approximately a 30% market share. The integration of the suppository formulation is expected to extend the product’s lifecycle, with China being recognized as the third-largest global market for mesalazine.- Flcube.com
